Evidence method
Level · gp.fundamentals.debt_to_revenue
100.89% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
AKBA · Jun 30, 2026
Akebia Therapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001517022-26-000051General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
2.20% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
7.18% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
-21.36% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
26.50% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
78.78% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-12.88% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
28.62% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
6.57% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History12 statesHistory building
Sep 30, 20230/8 normalizedLevel 3Dec 31, 20230/8 normalizedLevel 3Mar 31, 20240/7 normalizedLevel 3Jun 30, 20240/7 normalizedLevel 3Sep 30, 20240/9 normalizedLevel 3Dec 31, 20240/9 normalizedLevel 3Mar 31, 20250/9 normalizedLevel 3Jun 30, 20250/9 normalizedLevel 3Sep 30, 20257/9 normalizedLevel 3Dec 31, 20257/9 normalizedLevel 3Mar 31, 20268/9 normalizedLevel 3Jun 30, 20268/9 normalizedLevel 3
Period transition
What moved in the state?
- Previous
- 91.31%
- Current
- 100.89%
- Delta
- 9.58%
- Previous
- 0.12%
- Current
- 2.20%
- Delta
- 2.08%
- Previous
- -39.61%
- Current
- 7.18%
- Delta
- 46.78%
- Previous
- -6.61%
- Current
- -21.36%
- Delta
- -14.75%
- Previous
- 24.27%
- Current
- 26.50%
- Delta
- 2.23%
- Previous
- 77.05%
- Current
- 78.78%
- Delta
- 1.74%
- Previous
- -8.77%
- Current
- -12.88%
- Delta
- -4.11%
- Previous
- 27.65%
- Current
- 28.62%
- Delta
- 0.96%
- Previous
- 6.85%
- Current
- 6.57%
- Delta
- -0.28%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Compared To · Pharmaceutical Preparations peers →Transitioned To · AKBA Fundamental State →Transitioned To · AKBA BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · AKBA CAPEX_INTENSITY_INCREASED →Transitioned To · AKBA CASH_GENERATION_INCREASED →Transitioned To · AKBA GROWTH_DECREASED →Transitioned To · AKBA INVENTORY_PRESSURE_INCREASED →Transitioned To · AKBA MARGIN_INCREASED →Transitioned To · AKBA PROFITABILITY_DECREASED →Transitioned To · AKBA R_AND_D_INTENSITY_INCREASED →Transitioned To · AKBA SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.